Cost-Effectiveness of Afatinib, Gefitinib, Erlotinib, and Pemetrexed-Based Chemotherapy as First-Line Treatments for Egfr Mutation Positive, Advanced Non-Small Cell Lung Cancer in China

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.243
https://www.valueinhealthjournal.com/article/S1098-3015(17)30577-6/fulltext
Title : Cost-Effectiveness of Afatinib, Gefitinib, Erlotinib, and Pemetrexed-Based Chemotherapy as First-Line Treatments for Egfr Mutation Positive, Advanced Non-Small Cell Lung Cancer in China
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30577-6&doi=10.1016/j.jval.2017.08.243
First page : A440
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 221
Categories :
Tags :
Regions :
ViH Article Tags :